icon-folder.gif   Conference Reports for NATAP  
 
  EASL 48th Annual Meeting
April 24th - 28th 2013
The Netherlands, Amsterdam
Back grey_arrow_rt.gif
 
 
 
Simeprevir (TMC435) with peginterferon/ribavirin for chronic hCV genotype 1 infection in treatment-naïve patients: results from QUEST-1, a Phase III trial
 
 
  Reported by Jules Levin
48th Annual Meeting of the
European Association for the Study of the Liver
24 April - 28 April 2013 · Amsterdam, The Netherlands
 
Ira Jacobson,1 Gregory J Dore,2 Graham R Foster,3 Michael W Fried,4 Monica Radu,5 Vladimir V Rafalskiy,6 larysa Moroz,7 antonio Crax,8 Monika Peeters,9 Oliver lenz,9 sivi Ouwerkerk-Mahadevan,10 Ronald Kalmeijer,11 Maria Beumont-Mauviel9
 
1Weill Cornell Medical College, New York, NY, USA; 2Kirby Institute, University of New South Wales, Sydney, Australia; 3Queen Mary University of London, Barts Health, London, UK; 4University of North Carolina at Chapel Hill, NC, USA; 5Institutul de Boli infectioase, Bucharest, Romania; 6Smolensk Regional Clinical Hospital, Smolensk Oblast, Russia; 7Vinnytsia National Medical University, Vinnytsia, Ukraine; 8Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone, Palermo, Italy; 9Janssen Infectious Diseases BVBA, Beerse, Belgium; 10Jansssen Research & Development, Beerse, Belgium; 11Janssen Global Services, LLC, Titusville, NJ, USA

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

Figure6.gif

EASL7.gif

EASL8.gif

EASL9.gif